881TiP A multi-centre, open-label phase II trial of the combination of VB10.16 and atezolizumab in patients with advanced or recurrent, non-resectable HPV16 positive cervical cancer

Autor:	S. Torhaug, Kristina Lindemann, K. Schetne, A.B. Fredriksen, B. Nicolaisen, JF Baurain, P. Blecharz, Peter Hillemanns
Rok vydání:	2020
Předmět:	Cervical cancer medicine.medical_specialty Oncology business.industry Atezolizumab Medicine In patient Hematology Radiology Multi centre Open label business medicine.disease
Zdroj:	Annals of Oncology. 31:S645-S646
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.1020
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::79d4ee94b4fa6cb6d3e289dfd1c3adf9 https://doi.org/10.1016/j.annonc.2020.08.1020 Zobrazit plný text záznamu